In this 2019 review, Thomas Seyfried et al. argue that, due to the significant drawbacks of the existing standard of care for glioblastoma multiforme (GBM) and the potential benefits of ketogenic metabolic therapy, ketogenic therapies should be tested in patients with GBM.